We’re still in the early stages of RSV season, but doctors are already worried about a rise in cases. As we head into the peak of 2025 RSV season, parents are once again facing an uptick in cases, ...

COVID-19 was associated with more severe disease outcomes than influenza or respiratory syncytial virus (RSV) during ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study.

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

Vulnerable and elderly Australians are missing out on protection against respiratory syncytial virus (RSV) because many can’t ...

In the throes of winter's yearly round of respiratory virus outbreaks, it pays to remember what Grandma told you.

Pfizer said it will 'support capacity-building initiatives, such as training healthcare professionals and advancing clinical ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.